Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep 9;111(6):1132-8.
doi: 10.1038/bjc.2014.418. Epub 2014 Jul 29.

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

T Golan  1 , Z S Kanji  2 , R Epelbaum  3 , N Devaud  2 , E Dagan  4 , S Holter  2 , D Aderka  1 , S Paluch-Shimon  1 , B Kaufman  1 , R Gershoni-Baruch  5 , D Hedley  6 , M J Moore  6 , E Friedman  7 , S Gallinger  2
Affiliations

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

T Golan et al. Br J Cancer. .

Abstract

Background: The BRCA1/2 proteins are involved in regulation of cellular proliferation by DNA damage repair via homologous recombination. Therefore, BRCA1/2 mutation carriers with pancreatic cancer may have distinct biologic outcomes.

Methods: Patients with BRCA1/2-associated pancreatic ductal adenocarcinoma (PDAC) diagnosed between January 1994 and December 2012 were identified from databases at three participating institutions. Clinical data were collected. Disease-free survival and overall survival (OS) were analysed.

Results: Overall, 71 patients with PDAC and BRCA1 (n=21), BRCA2 (n=49) or both (n=1) mutations were identified. Mean age at diagnosis was 60.3 years (range 33-83), 81.7% (n=58) had any family history of malignancy; 30% (n=21) underwent primary resection. Out of 71 participants, 12 received experimental therapy; one patient had missing data, these 13 cases were excluded from OS analysis. Median OS for 58 patients was 14 months (95% CI 10-23 months). Median OS for patients with stage 1/2 disease has not been reached with 52% still alive at 60 months. Median OS for stage 3/4 was 12 months (95% CI 6-15). Superior OS was observed for patients with stage 3/4 treated with platinum vs those treated with non-platinum chemotherapies (22 vs 9 months; P=0.039).

Conclusion: Superior OS was observed for advanced-disease BRCA-associated PDAC with platinum exposure.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Probability of overall survival of all patients. (B) Probability of overall survival by BRCA mutations.
Figure 2
Figure 2
(A) Probability of overall survival by stage 1 or 2 (n=15). (B) Probability of overall survival by stage 3 or 4 (n=43). (C) Probability of overall survival by platinum treatment at stages 3 and 4.
See this image and copyright information in PMC

References

    1. Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007;110:738–744. - PubMed
    1. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, Van Der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers J. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010;17:688–695. - PMC - PubMed
    1. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917. - PubMed
    1. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97:2187–2195. - PubMed
    1. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol. 2008;26:20–25. - PubMed

MeSH terms